<!DOCTYPE html>
<html lang="en">
    <!-- title -->




<!-- keywords -->




<head><meta name="generator" content="Hexo 3.8.0">
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=no">
    <meta name="author" content="Hua">
    <meta name="renderer" content="webkit">
    <meta name="copyright" content="Hua">
    
    <meta name="keywords" content="hexo,hexo-theme,hexo-blog">
    
    <meta name="description" content="">
    <meta http-equiv="Cache-control" content="no-cache">
    <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
    <title>神经免疫类与外周血T淋巴细胞研究套路 · Hua的公告板</title>
    <style type="text/css">
    @font-face {
        font-family: 'Oswald-Regular';
        src: url("/font/Oswald-Regular.ttf");
    }

    body {
        margin: 0;
    }

    header,
    footer,
    .back-top,
    .sidebar,
    .container,
    .site-intro-meta,
    .toc-wrapper {
        display: none;
    }

    .site-intro {
        position: relative;
        z-index: 3;
        width: 100%;
        /* height: 50vh; */
        overflow: hidden;
    }

    .site-intro-placeholder {
        position: absolute;
        z-index: -2;
        top: 0;
        left: 0;
        width: calc(100% + 300px);
        height: 100%;
        background: repeating-linear-gradient(-45deg, #444 0, #444 80px, #333 80px, #333 160px);
        background-position: center center;
        transform: translate3d(-226px, 0, 0);
        animation: gradient-move 2.5s ease-out 0s infinite;
    }

    @keyframes gradient-move {
        0% {
            transform: translate3d(-226px, 0, 0);
        }
        100% {
            transform: translate3d(0, 0, 0);
        }
    }

</style>

    <link rel="preload" href="/css/style.css?v=20180824" as="style" onload="this.onload=null;this.rel='stylesheet'">
    <link rel="stylesheet" href="/css/mobile.css?v=20180824" media="(max-width: 980px)">
    
    <link rel="preload" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" as="style" onload="this.onload=null;this.rel='stylesheet'">
    
    <!-- /*! loadCSS. [c]2017 Filament Group, Inc. MIT License */
/* This file is meant as a standalone workflow for
- testing support for link[rel=preload]
- enabling async CSS loading in browsers that do not support rel=preload
- applying rel preload css once loaded, whether supported or not.
*/ -->
<script>
(function( w ){
	"use strict";
	// rel=preload support test
	if( !w.loadCSS ){
		w.loadCSS = function(){};
	}
	// define on the loadCSS obj
	var rp = loadCSS.relpreload = {};
	// rel=preload feature support test
	// runs once and returns a function for compat purposes
	rp.support = (function(){
		var ret;
		try {
			ret = w.document.createElement( "link" ).relList.supports( "preload" );
		} catch (e) {
			ret = false;
		}
		return function(){
			return ret;
		};
	})();

	// if preload isn't supported, get an asynchronous load by using a non-matching media attribute
	// then change that media back to its intended value on load
	rp.bindMediaToggle = function( link ){
		// remember existing media attr for ultimate state, or default to 'all'
		var finalMedia = link.media || "all";

		function enableStylesheet(){
			link.media = finalMedia;
		}

		// bind load handlers to enable media
		if( link.addEventListener ){
			link.addEventListener( "load", enableStylesheet );
		} else if( link.attachEvent ){
			link.attachEvent( "onload", enableStylesheet );
		}

		// Set rel and non-applicable media type to start an async request
		// note: timeout allows this to happen async to let rendering continue in IE
		setTimeout(function(){
			link.rel = "stylesheet";
			link.media = "only x";
		});
		// also enable media after 3 seconds,
		// which will catch very old browsers (android 2.x, old firefox) that don't support onload on link
		setTimeout( enableStylesheet, 3000 );
	};

	// loop through link elements in DOM
	rp.poly = function(){
		// double check this to prevent external calls from running
		if( rp.support() ){
			return;
		}
		var links = w.document.getElementsByTagName( "link" );
		for( var i = 0; i < links.length; i++ ){
			var link = links[ i ];
			// qualify links to those with rel=preload and as=style attrs
			if( link.rel === "preload" && link.getAttribute( "as" ) === "style" && !link.getAttribute( "data-loadcss" ) ){
				// prevent rerunning on link
				link.setAttribute( "data-loadcss", true );
				// bind listeners to toggle media back
				rp.bindMediaToggle( link );
			}
		}
	};

	// if unsupported, run the polyfill
	if( !rp.support() ){
		// run once at least
		rp.poly();

		// rerun poly on an interval until onload
		var run = w.setInterval( rp.poly, 500 );
		if( w.addEventListener ){
			w.addEventListener( "load", function(){
				rp.poly();
				w.clearInterval( run );
			} );
		} else if( w.attachEvent ){
			w.attachEvent( "onload", function(){
				rp.poly();
				w.clearInterval( run );
			} );
		}
	}


	// commonjs
	if( typeof exports !== "undefined" ){
		exports.loadCSS = loadCSS;
	}
	else {
		w.loadCSS = loadCSS;
	}
}( typeof global !== "undefined" ? global : this ) );
</script>

    <link rel="icon" href="/assets/favicon.ico">
    <link rel="preload" href="https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.min.js" as="script">
    <link rel="preload" href="https://cdn.jsdelivr.net/npm/jquery@3.3.1/dist/jquery.min.js" as="script">
    <link rel="preload" href="/scripts/main.js" as="script">
    <link rel="preload" as="font" href="/font/Oswald-Regular.ttf" crossorigin="">
    <link rel="preload" as="font" href="https://at.alicdn.com/t/font_327081_1dta1rlogw17zaor.woff" crossorigin="">
    
        <!-- algolia -->
        <script>
            
            var hits = JSON.parse('{"per_page":10}')
            var labels = JSON.parse('{"input_placeholder":"Search for Posts","hits_empty":"We did not find any results for the search: ${query}","hits_stats":"${hits} results found in ${time} ms"}')

            var algolia = {
                applicationID: 'ZKGZPC2HRL',
                apiKey: 'd14aa6ef670d284260dc375c7e565f5e',
                indexName: 'hexo_search',
                hits: hits,
                labels: labels
            }
        </script>
    
    <!-- fancybox -->
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" defer></script>
    <!-- 百度统计  -->
    
    <!-- 谷歌统计  -->
    
</head>

    
        <body class="post-body">
    
    
<header class="header">

    <div class="read-progress"></div>
    <div class="header-sidebar-menu">&#xe775;</div>
    <!-- post页的toggle banner  -->
    
    <div class="banner">
            <div class="blog-title">
                <a href="/">Hua的公告板</a>
            </div>
            <div class="post-title">
                <a href="#" class="post-name">神经免疫类与外周血T淋巴细胞研究套路</a>
            </div>
    </div>
    
    <a class="home-link" href="/">Hua的公告板</a>
</header>
    <div class="wrapper">
        <div class="site-intro" style="







height:50vh;
">
    
    <!-- 主页  -->
    
    
    <!-- 404页  -->
            
    <div class="site-intro-placeholder"></div>
    <div class="site-intro-img" style="background-image: url(/intro/post-bg.jpg)"></div>
    <div class="site-intro-meta">
        <!-- 标题  -->
        <h1 class="intro-title">
            <!-- 主页  -->
            
            神经免疫类与外周血T淋巴细胞研究套路
            <!-- 404 -->
            
        </h1>
        <!-- 副标题 -->
        <p class="intro-subtitle">
            <!-- 主页副标题  -->
            
            
            <!-- 404 -->
            
        </p>
        <!-- 文章页meta -->
        
            <div class="post-intros">
                <!-- 文章页标签  -->
                
                
                    <div class="post-intro-read">
                        <span>Word count: <span class="post-count word-count">713</span>Reading time: <span class="post-count reading-time">4 min</span></span>
                    </div>
                
                <div class="post-intro-meta">
                    <span class="post-intro-calander iconfont-archer">&#xe676;</span>
                    <span class="post-intro-time">2019/04/27</span>
                    
                    <span id="busuanzi_container_page_pv" class="busuanzi-pv">
                        <span class="iconfont-archer">&#xe602;</span>
                        <span id="busuanzi_value_page_pv"></span>
                    </span>
                    
                    <span class="shareWrapper">
                        <span class="iconfont-archer shareIcon">&#xe71d;</span>
                        <span class="shareText">Share</span>
                        <ul class="shareList">
                            <li class="iconfont-archer share-qr" data-type="qr">&#xe75b;
                                <div class="share-qrcode"></div>
                            </li>
                            <li class="iconfont-archer" data-type="weibo">&#xe619;</li>
                            <li class="iconfont-archer" data-type="qzone">&#xe62e;</li>
                            <li class="iconfont-archer" data-type="twitter">&#xe634;</li>
                            <li class="iconfont-archer" data-type="facebook">&#xe67a;</li>
                        </ul>
                    </span>
                </div>
            </div>
        
    </div>
</div>
        <script>
 
  // get user agent
  var browser = {
    versions: function () {
      var u = window.navigator.userAgent;
      return {
        userAgent: u,
        trident: u.indexOf('Trident') > -1, //IE内核
        presto: u.indexOf('Presto') > -1, //opera内核
        webKit: u.indexOf('AppleWebKit') > -1, //苹果、谷歌内核
        gecko: u.indexOf('Gecko') > -1 && u.indexOf('KHTML') == -1, //火狐内核
        mobile: !!u.match(/AppleWebKit.*Mobile.*/), //是否为移动终端
        ios: !!u.match(/\(i[^;]+;( U;)? CPU.+Mac OS X/), //ios终端
        android: u.indexOf('Android') > -1 || u.indexOf('Linux') > -1, //android终端或者uc浏览器
        iPhone: u.indexOf('iPhone') > -1 || u.indexOf('Mac') > -1, //是否为iPhone或者安卓QQ浏览器
        iPad: u.indexOf('iPad') > -1, //是否为iPad
        webApp: u.indexOf('Safari') == -1, //是否为web应用程序，没有头部与底部
        weixin: u.indexOf('MicroMessenger') == -1, //是否为微信浏览器
        uc: u.indexOf('UCBrowser') > -1 //是否为android下的UC浏览器
      };
    }()
  }
  console.log("userAgent:" + browser.versions.userAgent);

  // callback
  function fontLoaded() {
    console.log('font loaded');
    if (document.getElementsByClassName('site-intro-meta')) {
      document.getElementsByClassName('intro-title')[0].classList.add('intro-fade-in');
      document.getElementsByClassName('intro-subtitle')[0].classList.add('intro-fade-in');
      var postIntros = document.getElementsByClassName('post-intros')[0]
      if (postIntros) {
        postIntros.classList.add('post-fade-in');
      }
    }
  }

  // UC不支持跨域，所以直接显示
  function asyncCb(){
    if (browser.versions.uc) {
      console.log("UCBrowser");
      fontLoaded();
    } else {
      WebFont.load({
        custom: {
          families: ['Oswald-Regular']
        },
        loading: function () {  //所有字体开始加载
          // console.log('loading');
        },
        active: function () {  //所有字体已渲染
          fontLoaded();
        },
        inactive: function () { //字体预加载失败，无效字体或浏览器不支持加载
          console.log('inactive: timeout');
          fontLoaded();
        },
        timeout: 5000 // Set the timeout to two seconds
      });
    }
  }

  function asyncErr(){
    console.warn('script load from CDN failed, will load local script')
  }

  // load webfont-loader async, and add callback function
  function async(u, cb, err) {
    var d = document, t = 'script',
      o = d.createElement(t),
      s = d.getElementsByTagName(t)[0];
    o.src = u;
    if (cb) { o.addEventListener('load', function (e) { cb(null, e); }, false); }
    if (err) { o.addEventListener('error', function (e) { err(null, e); }, false); }
    s.parentNode.insertBefore(o, s);
  }

  var asyncLoadWithFallBack = function(arr, success, reject) {
      var currReject = function(){
        reject()
        arr.shift()
        if(arr.length)
          async(arr[0], success, currReject)
        }

      async(arr[0], success, currReject)
  }

  asyncLoadWithFallBack([
    "https://cdn.jsdelivr.net/npm/webfontloader@1.6.28/webfontloader.min.js", 
    "https://cdn.bootcss.com/webfont/1.6.28/webfontloader.js",
    "/lib/webfontloader.min.js"
  ], asyncCb, asyncErr)
</script>        
        <img class="loading" src="/assets/loading.svg" style="display: block; margin: 6rem auto 0 auto; width: 6rem; height: 6rem;" />
        <div class="container container-unloaded">
            <main class="main post-page">
    <article class="article-entry">
        <link rel="stylesheet" type="text/css" href="https://cdn.jsdelivr.net/hint.css/2.4.1/hint.min.css"><h3 id="总结"><a href="#总结" class="headerlink" title="总结"></a>总结</h3><figure class="highlight plain"><table><tr><td class="gutter"><pre><span class="line">1</span><br></pre></td><td class="code"><pre><span class="line">要么测试新药疗效，要么研究biomarker</span><br></pre></td></tr></table></figure>
<ul>
<li>检索范围：近三年，神经免疫类与外周血T淋巴细胞，JAMA neurology/ Neurology/lancet neurol</li>
</ul>
<h3 id="JAMA-neurology"><a href="#JAMA-neurology" class="headerlink" title="JAMA neurology"></a>JAMA neurology</h3><h4 id="Correlation-of-Peripheral-Immunity-With-Rapid-Amyotrophic-Lateral-Sclerosis-Progression-2017"><a href="#Correlation-of-Peripheral-Immunity-With-Rapid-Amyotrophic-Lateral-Sclerosis-Progression-2017" class="headerlink" title="Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. 2017"></a>Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28973548" target="_blank" rel="noopener">2017</a></h4><blockquote>
<p>To assess peripheral inflammatory markers in participants with ALS and healthy control individuals and to track immune changes in ALS and determine whether these changes correlate with disease progression.</p>
</blockquote>
<h4 id="Interpreting-Lymphocyte-Reconstitution-Data-From-the-Pivotal-Phase-3-Trials-of-Alemtuzumab-2017"><a href="#Interpreting-Lymphocyte-Reconstitution-Data-From-the-Pivotal-Phase-3-Trials-of-Alemtuzumab-2017" class="headerlink" title="Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. 2017"></a>Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. <a href="https://www.ncbi.nlm.nih.gov/pubmed/28604916" target="_blank" rel="noopener">2017</a></h4><blockquote>
<p>To investigate whether the data describing the effect of alemtuzumab on lymphocyte subsets collected during the phase 3 trial program reveal mechanisms explaining efficacy and the risk for secondary autoimmunity with treatment of MS.</p>
</blockquote>
<ul>
<li>Alemtuzumab depleted CD4+ T cells by more than 95%, including regulatory cells (-80%) and CD8+ T cells (&gt;80% depletion), which remained well below reference levels throughout the trials. </li>
</ul>
<h4 id="Immunologic-Effects-of-Metformin-and-Pioglitazone-Treatment-on-Metabolic-Syndrome-and-Multiple-Sclerosis-2016"><a href="#Immunologic-Effects-of-Metformin-and-Pioglitazone-Treatment-on-Metabolic-Syndrome-and-Multiple-Sclerosis-2016" class="headerlink" title="Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. 2016"></a>Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26953870" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>To determine whether metformin and/or pioglitazone are associated with a reduction in disease activity as measured by brain magnetic resonance imaging in patients with MS and MetS and to evaluate the potential mechanisms underlying this anti-inflammatory effect.</p>
</blockquote>
<ul>
<li>Both metformin and pioglitazone resulted in a significant increase in the number and regulatory functions of CD4+CD25+FoxP3+ regulatory T cells compared with controls (metformin, 6.7 [1.5] vs 2.1 [1.0], P = .001; pioglitazone, 6.9 [0.8] vs 3.0 [0.8], P = .001).</li>
</ul>
<h4 id="Immunophenotyping-of-cerebrospinal-fluid-cells-in-multiple-sclerosis-in-search-of-biomarkers-2014"><a href="#Immunophenotyping-of-cerebrospinal-fluid-cells-in-multiple-sclerosis-in-search-of-biomarkers-2014" class="headerlink" title="Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. 2014"></a>Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. <a href="https://www.ncbi.nlm.nih.gov/pubmed/24818670" target="_blank" rel="noopener">2014</a></h4><blockquote>
<p>MS中CSF的细胞学检测</p>
</blockquote>
<h4 id="Disease-amelioration-with-tocilizumab-in-a-treatment-resistant-patient-with-neuromyelitis-optica-implication-for-cellular-immune-responses-2013"><a href="#Disease-amelioration-with-tocilizumab-in-a-treatment-resistant-patient-with-neuromyelitis-optica-implication-for-cellular-immune-responses-2013" class="headerlink" title="Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. 2013"></a>Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. <a href="https://www.ncbi.nlm.nih.gov/pubmed/23599943" target="_blank" rel="noopener">2013</a></h4><blockquote>
<p>To study clinical and paraclinical effects of tocilizumab in a patient with NMO.</p>
</blockquote>
<h3 id="Neurology"><a href="#Neurology" class="headerlink" title="Neurology"></a>Neurology</h3><h4 id="Vitiligo-after-alemtuzumab-treatment-Secondary-autoimmunity-is-not-all-about-B-cells-2018"><a href="#Vitiligo-after-alemtuzumab-treatment-Secondary-autoimmunity-is-not-all-about-B-cells-2018" class="headerlink" title="Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. 2018"></a>Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30404783" target="_blank" rel="noopener">2018</a></h4><blockquote>
<p>To report 3 patients with relapsing-remitting <strong>multiple sclerosis</strong> (RRMS) showing vitiligo after treatment with alemtuzumab.</p>
</blockquote>
<ul>
<li>Histopathology shows loss of epidermal pigmentation with absence of melanocytes and interface dermatitis with CD8+ T-cell infiltration. Also compatible with pathophysiologic concepts of vitiligo, peripheral blood mononuclear cells of one patient showed high proportions of CD8+ T cells with an activated (human leukocyte antigen-DR+), memory (CD45RO+), and type 1 cytokine (interferon-γ + tumor necrosis factor-α) phenotype at vitiligo onset compared to a control cohort of alemtuzumab-treated patients with RRMS (n = 30). Of note, analysis of CD8 TCR repertoire in this patient revealed a highly increased clonality and reduced repertoire diversity compared to healthy controls and treatment-naive patients with RRMS. </li>
</ul>
<h4 id="Safety-and-immunologic-effects-of-high-vs-low-dose-cholecalciferol-in-multiple-sclerosis-2016"><a href="#Safety-and-immunologic-effects-of-high-vs-low-dose-cholecalciferol-in-multiple-sclerosis-2016" class="headerlink" title="Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. 2016"></a>Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26718578" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>To study the safety profile and characterize the immunologic effects of high- vs low-dose cholecalciferol supplementation in patients with multiple sclerosis (MS).</p>
</blockquote>
<ul>
<li>In the high-dose group, we found a reduction in the proportion of interleukin-17(+)CD4(+) T cells (p = 0.016), CD161(+)CD4(+) T cells (p = 0.03), and effector memory CD4(+) T cells (p = 0.021) with a concomitant increase in the proportion of central memory CD4(+) T cells (p = 0.018) and naive CD4(+) T cells (p = 0.04). These effects were not observed in the low-dose group.</li>
</ul>
<h4 id="CD62L-is-not-a-reliable-biomarker-for-predicting-PML-risk-in-natalizumab-treated-R-MS-patients-2016"><a href="#CD62L-is-not-a-reliable-biomarker-for-predicting-PML-risk-in-natalizumab-treated-R-MS-patients-2016" class="headerlink" title="CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients 2016"></a>CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients <a href="https://www.ncbi.nlm.nih.gov/pubmed/26718566" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>To assess if the percentage of CD3(+)CD4(+)CD62L(+) cells in cryopreserved peripheral blood mononuclear cells (PBMCs) (here termed %CD62L) can predict risk of developing progressive multifocal leukoencephalopathy (PML) and better inform the physician for benefit-risk assessment of natalizumab treatment decisions in a global setting.</p>
</blockquote>
<h4 id="Immunopathophysiology-of-pediatric-CNS-inflammatory-demyelinating-diseases-2016"><a href="#Immunopathophysiology-of-pediatric-CNS-inflammatory-demyelinating-diseases-2016" class="headerlink" title="Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. 2016"></a>Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. <a href="https://www.ncbi.nlm.nih.gov/pubmed/27572856" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>综述</p>
</blockquote>
<ul>
<li>Emerging results implicate abnormalities in both effector and regulatory T cell subsets, and potentially immune senescence, in children with MS. </li>
</ul>
<h3 id="lancet-neurol"><a href="#lancet-neurol" class="headerlink" title="lancet neurol"></a>lancet neurol</h3><h4 id="The-search-for-the-target-antigens-of-multiple-sclerosis-part-1-autoreactive-CD4-T-lymphocytes-as-pathogenic-effectors-and-therapeutic-targets-2016"><a href="#The-search-for-the-target-antigens-of-multiple-sclerosis-part-1-autoreactive-CD4-T-lymphocytes-as-pathogenic-effectors-and-therapeutic-targets-2016" class="headerlink" title="The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. 2016"></a>The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26724103" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>综述</p>
</blockquote>
<h4 id="The-search-for-the-target-antigens-of-multiple-sclerosis-part-2-CD8-T-cells-B-cells-and-antibodies-in-the-focus-of-reverse-translational-research-2016"><a href="#The-search-for-the-target-antigens-of-multiple-sclerosis-part-2-CD8-T-cells-B-cells-and-antibodies-in-the-focus-of-reverse-translational-research-2016" class="headerlink" title="The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. 2016"></a>The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. <a href="https://www.ncbi.nlm.nih.gov/pubmed/26724102" target="_blank" rel="noopener">2016</a></h4><blockquote>
<p>综述</p>
</blockquote>
<h4 id="Immune-dysregulation-in-amyotrophic-lateral-sclerosis-mechanisms-and-emerging-therapies-2019"><a href="#Immune-dysregulation-in-amyotrophic-lateral-sclerosis-mechanisms-and-emerging-therapies-2019" class="headerlink" title="Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. 2019"></a>Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30663610" target="_blank" rel="noopener">2019</a></h4><blockquote>
<p>综述</p>
</blockquote>

    </article>
    <!-- license  -->
    
        <div class="license-wrapper">
            <p>Author：<a href="https://cpresident.github.io">Hua</a>
            </p><p>原文链接：<a href="https://cpresident.github.io/p/a0b7.html">https://cpresident.github.io/p/a0b7.html</a>
            </p><p>发表日期：<a href="https://cpresident.github.io/p/a0b7.html">April 27th 2019, 2:28:00 pm</a>
            </p><p>更新日期：<a href="https://cpresident.github.io/p/a0b7.html">April 27th 2019, 3:39:59 pm</a>
            </p><p>版权声明：</p>
        </div>
    
    <!-- paginator  -->
    <ul class="post-paginator">
        <li class="next">
            
        </li>
        <li class="previous">
            
                <div class="prevSlogan">Previous Post</div>
                <a href="/p/ef21.html" title="TCM和TEM">
                    <div class="prevTitle">TCM和TEM</div>
                </a>
            
        </li>
    </ul>
    <!-- 评论插件 -->
    <!-- 来必力City版安装代码 -->

<!-- City版安装代码已完成 -->
    
    
    <!-- partial('_partial/comment/changyan') -->
    <!--PC版-->


    
    

    <!-- 评论 -->
</main>
            <!-- profile -->
            
        </div>
        <footer class="footer footer-unloaded">
    <!-- social  -->
    
    <div class="social">
        
    
        
            
                <a href="mailto:xvpresident@gmail.com" class="iconfont-archer email" title="email"></a>
            
        
    
        
    
        
    
        
    
        
            
                <a href="//t.me/iiijhh" class="iconfont-archer telegram" target="_blank" title="telegram"></a>
            
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
    
        
            
                <a href="/atom.xml" class="iconfont-archer rss" target="_blank" title="rss"></a>
            
        
    

    </div>
    
    <!-- powered by Hexo  -->
    <div class="copyright">
        <span id="hexo-power">Powered by <a href="https://hexo.io/" target="_blank">Hexo</a></span><span class="iconfont-archer power">&#xe635;</span><span id="theme-info">theme <a href="https://github.com/fi3ework/hexo-theme-archer" target="_blank">Archer</a></span>
    </div>
    <!-- 不蒜子  -->
    
    <div class="busuanzi-container">
    
     
    <span id="busuanzi_container_site_pv">PV: <span id="busuanzi_value_site_pv"></span> :)</span>
    
    </div>
    
</footer>
    </div>
    <!-- toc -->
    
    <div class="toc-wrapper" style=
    







top:50vh;

    >
        <div class="toc-catalog">
            <span class="iconfont-archer catalog-icon">&#xe613;</span><span>CATALOG</span>
        </div>
        <ol class="toc"><li class="toc-item toc-level-3"><a class="toc-link" href="#总结"><span class="toc-number">1.</span> <span class="toc-text">总结</span></a></li><li class="toc-item toc-level-3"><a class="toc-link" href="#JAMA-neurology"><span class="toc-number">2.</span> <span class="toc-text">JAMA neurology</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#Correlation-of-Peripheral-Immunity-With-Rapid-Amyotrophic-Lateral-Sclerosis-Progression-2017"><span class="toc-number">2.1.</span> <span class="toc-text">Correlation of Peripheral Immunity With Rapid Amyotrophic Lateral Sclerosis Progression. 2017</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Interpreting-Lymphocyte-Reconstitution-Data-From-the-Pivotal-Phase-3-Trials-of-Alemtuzumab-2017"><span class="toc-number">2.2.</span> <span class="toc-text">Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab. 2017</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Immunologic-Effects-of-Metformin-and-Pioglitazone-Treatment-on-Metabolic-Syndrome-and-Multiple-Sclerosis-2016"><span class="toc-number">2.3.</span> <span class="toc-text">Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis. 2016</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Immunophenotyping-of-cerebrospinal-fluid-cells-in-multiple-sclerosis-in-search-of-biomarkers-2014"><span class="toc-number">2.4.</span> <span class="toc-text">Immunophenotyping of cerebrospinal fluid cells in multiple sclerosis: in search of biomarkers. 2014</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Disease-amelioration-with-tocilizumab-in-a-treatment-resistant-patient-with-neuromyelitis-optica-implication-for-cellular-immune-responses-2013"><span class="toc-number">2.5.</span> <span class="toc-text">Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. 2013</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#Neurology"><span class="toc-number">3.</span> <span class="toc-text">Neurology</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#Vitiligo-after-alemtuzumab-treatment-Secondary-autoimmunity-is-not-all-about-B-cells-2018"><span class="toc-number">3.1.</span> <span class="toc-text">Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells. 2018</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Safety-and-immunologic-effects-of-high-vs-low-dose-cholecalciferol-in-multiple-sclerosis-2016"><span class="toc-number">3.2.</span> <span class="toc-text">Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis. 2016</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#CD62L-is-not-a-reliable-biomarker-for-predicting-PML-risk-in-natalizumab-treated-R-MS-patients-2016"><span class="toc-number">3.3.</span> <span class="toc-text">CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients 2016</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Immunopathophysiology-of-pediatric-CNS-inflammatory-demyelinating-diseases-2016"><span class="toc-number">3.4.</span> <span class="toc-text">Immunopathophysiology of pediatric CNS inflammatory demyelinating diseases. 2016</span></a></li></ol></li><li class="toc-item toc-level-3"><a class="toc-link" href="#lancet-neurol"><span class="toc-number">4.</span> <span class="toc-text">lancet neurol</span></a><ol class="toc-child"><li class="toc-item toc-level-4"><a class="toc-link" href="#The-search-for-the-target-antigens-of-multiple-sclerosis-part-1-autoreactive-CD4-T-lymphocytes-as-pathogenic-effectors-and-therapeutic-targets-2016"><span class="toc-number">4.1.</span> <span class="toc-text">The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets. 2016</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#The-search-for-the-target-antigens-of-multiple-sclerosis-part-2-CD8-T-cells-B-cells-and-antibodies-in-the-focus-of-reverse-translational-research-2016"><span class="toc-number">4.2.</span> <span class="toc-text">The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. 2016</span></a></li><li class="toc-item toc-level-4"><a class="toc-link" href="#Immune-dysregulation-in-amyotrophic-lateral-sclerosis-mechanisms-and-emerging-therapies-2019"><span class="toc-number">4.3.</span> <span class="toc-text">Immune dysregulation in amyotrophic lateral sclerosis: mechanisms and emerging therapies. 2019</span></a></li></ol></li></ol>
    </div>
    
    <div class="back-top iconfont-archer">&#xe639;</div>
    <div class="sidebar sidebar-hide">
    <ul class="sidebar-tabs sidebar-tabs-active-0">
        <li class="sidebar-tab-archives"><span class="iconfont-archer">&#xe67d;</span><span class="tab-name">Archive</span></li>
        <li class="sidebar-tab-tags"><span class="iconfont-archer">&#xe61b;</span><span class="tab-name">Tag</span></li>
        <li class="sidebar-tab-categories"><span class="iconfont-archer">&#xe666;</span><span class="tab-name">Cate</span></li>
    </ul>
    <div class="sidebar-content sidebar-content-show-archive">
          <div class="sidebar-panel-archives">
    <!-- 在ejs中将archive按照时间排序 -->
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    <div class="total-and-search">
        <div class="total-archive">
        Total : 14
        </div>
        <!-- search  -->
        
            <div class="site-search popup-trigger">
                <span class="iconfont-archer search-icon">&#xe627;</span>
            </div>
        
    </div>
    
    <div class="post-archive">
    
    
    
    
    <div class="archive-year"> 2019 </div>
    <ul class="year-list">
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">04/27</span><a class="archive-post-title" href="/p/a0b7.html">神经免疫类与外周血T淋巴细胞研究套路</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">04/17</span><a class="archive-post-title" href="/p/ef21.html">TCM和TEM</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">03/14</span><a class="archive-post-title" href="/p/5848.html">HLA in Myasthenia gravis【V4.5.1】报告</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">03/12</span><a class="archive-post-title" href="/p/8e00.html">HLA in Myasthenia gravis【V4.5】报告</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">03/01</span><a class="archive-post-title" href="/p/94c7.html">HLA in Myasthenia gravis【稿4】报告</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">02/08</span><a class="archive-post-title" href="/p/3563.html">HLA in Myasthenia gravis【稿3】插图及表格</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">02/04</span><a class="archive-post-title" href="/p/35ac.html">GCSRT课程</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">02/04</span><a class="archive-post-title" href="/p/4e76.html">HLA in Myasthenia gravis【稿3】报告</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">02/02</span><a class="archive-post-title" href="/p/b5c6.html">Treg cell的发生发展</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">01/22</span><a class="archive-post-title" href="/p/e83a.html">HLA in Myasthenia gravis 【稿2】 报告</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">01/18</span><a class="archive-post-title" href="/p/2d4a.html">HLA in Myasthenia gravis 【Meta可行性分析】</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">01/15</span><a class="archive-post-title" href="/p/ac35.html">HLA in Myasthenia gravis 【稿1】 报告</a>
        </li>
    
    
    
    
    
        </ul>
    
    <div class="archive-year"> 2018 </div>
    <ul class="year-list">
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">12/31</span><a class="archive-post-title" href="/p/3d25.html">HLA and Myasthenia gravis【R环境下Biblioshiny分析报告】</a>
        </li>
    
    
        <li class="archive-post-item">
            <span class="archive-post-date">12/28</span><a class="archive-post-title" href="/p/e9d9.html">BCR is the New Antibody, TCR is still a T Cell Receptor</a>
        </li>
    
    </ul></div>
  </div>
        <div class="sidebar-panel-tags">
    <div class="sidebar-tags-name">
    
    </div>
    <div class="iconfont-archer sidebar-tags-empty">&#xe678;</div>
    <div class="tag-load-fail" style="display: none; color: #ccc; font-size: 0.6rem;">
    缺失模块。<br>
    1、请确保node版本大于6.2<br>
    2、在博客根目录（注意不是archer根目录）执行以下命令：<br>
    <span style="color: #f75357; font-size: 1rem; line-height: 2rem;">npm i hexo-generator-json-content --save</span><br>
    3、在根目录_config.yml里添加配置：
    <pre style="color: #787878; font-size: 0.6rem;">
jsonContent:
  meta: false
  pages: false
  posts:
    title: true
    date: true
    path: true
    text: false
    raw: false
    content: false
    slug: false
    updated: false
    comments: false
    link: false
    permalink: false
    excerpt: false
    categories: true
    tags: true</pre>
    </div> 
    <div class="sidebar-tags-list"></div>
</div>
        <div class="sidebar-panel-categories">
    <div class="sidebar-categories-name">
    
    </div>
    <div class="iconfont-archer sidebar-categories-empty">&#xe678;</div>
    <div class="sidebar-categories-list"></div>
</div>
    </div>
</div> 
    <script>
    var siteMeta = {
        root: "/",
        author: "Hua"
    }
</script>
    <!-- CDN failover -->
    <script src="https://cdn.jsdelivr.net/npm/jquery@3.3.1/dist/jquery.min.js"></script>
    <script type="text/javascript">
        if (typeof window.$ === 'undefined')
        {
            console.warn('jquery load from jsdelivr failed, will load local script')
            document.write('<script src="/lib/jquery.min.js">\x3C/script>')
        }
    </script>
    <script src="/scripts/main.js"></script>
    <!-- algolia -->
    
        <div class="site-search">
  <div class="algolia-popup popup">
    <div class="algolia-search">
      <div class="algolia-search-input-icon">
        <i class="fa fa-search"></i>
      </div>
      <div class="algolia-search-input" id="algolia-search-input"></div>
    </div>

    <div class="algolia-results">
      <div id="algolia-stats"></div>
      <div id="algolia-hits"></div>
      <div id="algolia-pagination" class="algolia-pagination"></div>
    </div>

    <span class="popup-btn-close">
      <i class="iconfont-archer">&#xe609;</i>
    </span>
  </div>
</div>
        <script src="https://cdn.jsdelivr.net/npm/instantsearch.js@2.8.0/dist/instantsearch.min.js" defer></script>
        <script src="/scripts/search.js" defer></script>
    
    <!-- busuanzi  -->
    
    <script async src="//busuanzi.ibruce.info/busuanzi/2.3/busuanzi.pure.mini.js"></script>
    
    <!-- CNZZ  -->
    
    </div>
    <!-- async load share.js -->
    
        <script src="/scripts/share.js" async></script>    
     
    </body>
</html>


